In breast cancer, the word 'detection' is most commonly used to mean breast cancer screening, most commonly using mammography. Breast cancer diagnosis involves the characterization of a suspicious mass or imaging finding, and entails tissue sampling to make a definitive diagnosis of cancer versus benign disease. Most primary cancers are detected by physical examination or mammography during screening. The level of fluorodeoxyglucose (FDG) uptake in primary breast neoplasms reflects the rate of glucose metabolism and has been correlated with known prognostic factors and biologic characteristics such as tumor size, histologic type (higher uptake in ductal versus lobular), tumor histologic grade, and some indices of cellular proliferation (higher uptake with higher levels of proliferation). [6][7][8][9][10][11] Overall, the sensitivity of FDG positron-emission tomography (PET) in detecting primary breast cancer is 64-96 %, specificity is 73-100 %, positive predictive value is 81-100 %, and negative predictive value is 52-89 %, 1 but in one large study 12 the sensitivity was 57 % for lesions <1 cm compared with 91 % for tumors >1 cm and 25 % for in situ carcinoma. Another study confirmed the relatively poor sensitivity of whole-body FDG PET with small tumors (<1 cm), lobular histologic type, and well-differentiated in situ breast carcinoma. 13 As primary breast cancer detection requires the ability to depict occult, non-palpable, small (<1 cm) invasive, and in situ malignant lesions, whole-body FDG PET is not used in primary breast cancer detection. 
Staging at Presentation
The extent of spread at presentation is one of the most important prognostic factors for breast carcinoma. 18 Staging is typically divided into locoregional staging (for regional nodes, especially axillary nodes) and distant or systemic staging (for sites beyond locoregional nodes). The role of imaging in initial staging of breast cancer patients should be carefully considered in terms of performance and cost-benefit analysis. For example, the utility in staging asymptomatic patients with early breast cancer for distant metastases at presentation using conventional imaging (CI) has been shown to be very low in a number of studies, with overall prevalence of distant metastasis of under 2.5 %. [19] [20] [21] [22] [23] The experience of using whole-body FDG PET and PET-computed tomography (PET-CT) in the initial staging of early breast cancer is small, but has also confirmed these findings. 24, 25 In this population with a low prevalence of disease at distant sites, the false/true-positive ratio is too high (with any imaging modality) to be cost-effective and could lead to many unnecessary additional tests and biopsies. For these reasons, whole-body FDG PET-CT should be avoided in patients with early breast cancer.
Axillary Staging
For all patients with newly diagnosed invasive disease (all stages), the status of the axillary nodes is important for prognosis and determining adjuvant therapy. [26] [27] [28] For this reason, and since axillary nodes are easily accessible, axillary node status is confirmed following removal and histologic examination. Sentinel lymph node biopsy (SNLB) has gained widespread acceptance over the last 10 years to minimize the invasiveness of sampling axillary modes in patients with early breast cancer (tumor <2 cm on mammography, ultrasound, or breast MR and
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Figure 1: Left Breast Cancer with Axillary Lymph Node Metastasis at the Time of Diagnosis
A 45-year-old woman with abnormal microscopic calcifications detected on screening mammography. Biopsy revealed infiltrating ductal carcinoma with ER(+), PR(+), Her2/neu(-) histology. Axial (A and B) and coronal (C) positron-emission tomography-computed tomography (PET-CT) images show hypermetabolic activity in the left breast (A) and left axilla (B and C), which are consistent with her left breast cancer and axillary lymph node metastasis.
Figure 2: Recurrent Breast Cancer in Locoregional and Intrathoracic Lymph Nodes
A 48-year-old woman with history of inflammatory breast cancer that was resected. Her breast cancer was negative for the expression of hormone receptors (both estrogen and progesterone) and positive for the expression of HER2 receptor at histology. Axial positron-emission tomography-computed tomography (PET-CT) images of the upper (A) and mid (B) chest demonstrate recurrent disease extending into the axillary, supraclavicular, cervical, mediastinal, and hilar lymph nodes.
clinically negative axillae). This procedure spares many patients the morbidity associated with complete axillary lymph node dissection (ALND). The reported false-negative rate of SNLB of 5-10 % (with no false-positives) has contributed to making this the standard method of staging the axilla in patients with early breast cancer.
29-31
Many early studies of FDG PET focused on detecting axillary 83 Metastases from breast cancer can produce a 84 were the first investigators to correlate the diagnostic performance of FDG PET and bone scintigraphy with the morphologic appearance of individual skeletal metastases at plain film radiography or CT. They showed that FDG PET was superior to bone scintigraphy in the detection of osteolytic metastases, and bone scintigraphy detected significantly more osteoblastic metastases. Others have corroborated these findings, [85] [86] [87] [88] [89] leading to the general conclusion that FDG PET and bone scintigraphy are The combined PET and CT system (PET-CT) has emerged as a routine method of restaging many oncologic patients. 93 Fusion of anatomic and metabolic information generally leads to an increase in diagnostic confidence, as shown in an early retrospective study. 94 Several of the large retrospective studies of patients being restaged after primary treatment for breast cancer comparing the diagnostic performance of PET-CT with contrast-enhanced CT alone, PET alone, or side-by-side evaluation of CT and PET are summarized in Table 1 . [94] [95] [96] [97] [98] [99] [100] [101] Fused PET-CT data consistently detected more malignant foci in these studies;
however, on patient-based analysis they showed marginal (no statistical difference) improvement in sensitivity and specificity for the detection of recurrences. Improvement in accuracy occurred in evaluation of mediastinal and cervical lymph nodes and the skeleton (increased sensitivity for osteoblastic metastases).
96,99,100
Treatment Response
Breast cancer is one of the more responsive solid tumors, and there is an ever-increasing choice of effective systemic therapies for breast cancer. 102 Evaluating the efficacy of systemic treatment is an important diagnostic need for breast cancer. The two settings where imaging plays an important role in response to systemic therapy are patients with LABC (undergoing neoadjuvant therapy) and patients with metastatic, stage IV disease.
Locally Advanced Disease
Although neodajuvant therapy, compared with adjuvant therapy, has not been shown to improve survival, it does improve surgical options and provide prognostic information. 103 Studies have demonstrated that the extent of residual breast and axillary disease after treatment is prognostic for both disease-free survival (DFS) and overall survival (OS). [104] [105] [106] Patients demonstrating complete pathologic response (pCR), defined as no residual invasive tumor on histopathology at post-therapy surgery, have improved long-term outcome compared with patients without pCR. 104, 106 One of the primary aims of neo-adjuvant therapy is therefore to assess the response of the primary tumor to the treatment regimen. 103 Size-based approaches such as physical exam and mammography have trouble distinguishing pCR from other responses. 104, 107 This is therefore a role where functional imaging, with its ability to serially quantify metabolic changes in the tumor earlier than morphologic changes, may be particularly helpful.
Studies evaluating FDG PET for treatment response in LABC (reviewed in reference 108) have compared standardized uptake value (SUV), a semi-quantitative measure of glycolytic activity, at pre-treatment examination with values at varying times during (early and mid-point), and following completion of treatment (see Table 2 ). The studies in which the mid-point of therapy was evaluated showed that a drop of approximately 50 % or more in SUV from baseline predicted a good response. [109] [110] [111] [112] [113] [114] [115] [116] Studies evaluating change in FDG uptake early in the course of therapy (after one or two cycles) suggest that early assessment of response is possible and predictive of subsequent pathologic response. [112] [113] [114] [115] [116] [117] [118] [119] In a large prospective, multicenter trial of 104 patients with LABC being monitored with FDG PET during neoadjuvant therapy, a threshold of 45 % decrease in SUV after the first cycle of therapy correctly identified 11 of 15 histologic responders and the non-responders with a negative predictive value of 90 %, and similar 
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results were found after the second cycle using a threshold of 55 % relative decrease in SUV. 119 The MR is a more sensitive technique for the detection of residual disease but has relatively poor specificity, with sensitivity of 98 % and specificity of 40 % in differentiating minimal residual from gross residual disease in one study. 121 In patients with gross residual disease, post-therapy FDG PET has been shown to complement MRI to help define the extent of residual disease. 123 The combination of these two imaging modalities time-point after initiation of therapy to evaluate MBC with FDG has not been fully determined but may be as early as after the first cycle of therapy. The level of FDG uptake after therapy, again similar to neoadjuvant studies, has also shown to be predictive of outcome in patients completing a course of high-dose chemotherapy. 130 A particularly vexing clinical problem for breast cancer clinicians is the evaluation of response of skeletal metastases. 131 Changes in bone scintigraphy, the standard method of evaluation of patients with bone metastases, may significantly lag response or even 'flare' in response to successful treatment. 132, 133 The differences seen between bone scintigraphy and FDG PET for bone metastases have led to some investigation into the use of serial FDG PET in assessing bone metastasis response (see Figure 3) . In a retrospective study, Stafford et al. 134 showed that, in patients with FDG-positive bone-dominant metastatic disease, SUV changes of an index lesion on serial FDG PET correlated with clinical assessment of response and change in tumor marker value. Comparing serial changes in SUV of index lesions to patient outcome measures, Specht et al. 135 showed that percentage change in SUV is predictive of time to progression. In this retrospective study, a median decline of 41 % or greater was associated with a longer time to progression.
FDG PET-CT is ideally suited for evaluating treatment response of skeletal metastases in breast cancer patients since this technique provides accurate registration of metabolic and morphologic information. Tateishi et al. 136 showed, in a retrospective study of 102 patients with breast cancer skeletal metastasis undergoing systemic treatment, that a concomitant increase in CT attenuation and decrease in FDG SUV of the index lesion is predictive of a more durable response to therapy. Larger prospective trials are warranted to confirm these initial observations.
Characterization of Disease
As the array of available treatments for breast cancer increases and therapy is increasingly targeted, there is a growing need to help direct 
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